| Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents. | |
| | |
MedLine Citation:
|
PMID: 21034401 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Vascular endothelial growth factor receptor (VEGFR) is an important receptor tyrosine kinase (RTK) in the induction of angiogenesis. Abnormal activation of VEGFR leads to several disorders including cancer. Nowadays, inhibition of VEGFR kinase has been one of the most powerful clinical strategies in cancer treatment and great efforts to design and synthesize small molecular VEGFR inhibitors for cancer research have been made in recent years. This review highlights the major progress and development of them, including their structure and pharmacophore features, biological activities and structure-activity relationships (SAR). Special attentions are paid to the compounds available in market or in advanced clinical stages. |
| | |
Authors:
|
Dan Xu; Tianlin L Wang; Li-Ping Sun; Qi-Dong You |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Mini reviews in medicinal chemistry Volume: 11 ISSN: 1875-5607 ISO Abbreviation: Mini Rev Med Chem Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-01-17 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101094212 Medline TA: Mini Rev Med Chem Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 18-31 Citation Subset: IM |
Affiliation:
|
Department of Medicinal Chemistry, China Pharmaceutical University, No. 24, Tongjiaxiang Rd, Nanjing, 210009, Jiangsu Province, P.R. China. youqidong@gmail.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: How can we reduce alcohol-related road crash deaths among young Australians?
Next Document: Cardiovascular effects of glucagon-like Peptide 1.